-
Je něco špatně v tomto záznamu ?
Albumin administration prevents neurological damage and death in a mouse model of severe neonatal hyperbilirubinemia
S. Vodret, G. Bortolussi, AB. Schreuder, J. Jašprová, L. Vitek, HJ. Verkade, AF. Muro,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
Nature Open Access
od 2011-12-01
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Health & Medicine (ProQuest)
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
Springer Nature OA/Free Journals
od 2011-12-01
PubMed
26541892
DOI
10.1038/srep16203
Knihovny.cz E-zdroje
- MeSH
- bilirubin krev MeSH
- fototerapie metody MeSH
- lidé MeSH
- modely nemocí na zvířatech MeSH
- mozeček účinky léků MeSH
- myši MeSH
- nemoci nervového systému etiologie prevence a kontrola MeSH
- novorozenecká hyperbilirubinemie krev komplikace MeSH
- novorozenecká žloutenka krev komplikace MeSH
- sérový albumin aplikace a dávkování MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Therapies to prevent severe neonatal unconjugated hyperbilirubinemia and kernicterus are phototherapy and, in unresponsive cases, exchange transfusion, which has significant morbidity and mortality risks. Neurotoxicity is caused by the fraction of unconjugated bilirubin not bound to albumin (free bilirubin, Bf). Human serum albumin (HSA) administration was suggested to increase plasma bilirubin-binding capacity. However, its clinical use is infrequent due to difficulties to address its potential preventive and curative benefits, and to the absence of reliable markers to monitor bilirubin neurotoxicity risk. We used a genetic mouse model of unconjugated hyperbilirubinemia showing severe neurological impairment and neonatal lethality. We treated mutant pups with repeated HSA administration since birth, without phototherapy application. Daily intraperitoneal HSA administration completely rescued neurological damage and lethality, depending on dosage and administration frequency. Albumin infusion increased plasma bilirubin-binding capacity, mobilizing bilirubin from tissues to plasma. This resulted in reduced plasma Bf, forebrain and cerebellum bilirubin levels. We showed that, in our experimental model, Bf is the best marker to determine the risk of developing neurological damage. These results support the potential use of albumin administration in severe acute hyperbilirubinemia conditions to prevent or treat bilirubin neurotoxicity in situations in which exchange transfusion may be required.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16027994
- 003
- CZ-PrNML
- 005
- 20161005131417.0
- 007
- ta
- 008
- 161005s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/srep16203 $2 doi
- 024 7_
- $a 10.1038/srep16203 $2 doi
- 035 __
- $a (PubMed)26541892
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Vodret, Simone $u International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 99 - 34149 - Trieste, Italy.
- 245 10
- $a Albumin administration prevents neurological damage and death in a mouse model of severe neonatal hyperbilirubinemia / $c S. Vodret, G. Bortolussi, AB. Schreuder, J. Jašprová, L. Vitek, HJ. Verkade, AF. Muro,
- 520 9_
- $a Therapies to prevent severe neonatal unconjugated hyperbilirubinemia and kernicterus are phototherapy and, in unresponsive cases, exchange transfusion, which has significant morbidity and mortality risks. Neurotoxicity is caused by the fraction of unconjugated bilirubin not bound to albumin (free bilirubin, Bf). Human serum albumin (HSA) administration was suggested to increase plasma bilirubin-binding capacity. However, its clinical use is infrequent due to difficulties to address its potential preventive and curative benefits, and to the absence of reliable markers to monitor bilirubin neurotoxicity risk. We used a genetic mouse model of unconjugated hyperbilirubinemia showing severe neurological impairment and neonatal lethality. We treated mutant pups with repeated HSA administration since birth, without phototherapy application. Daily intraperitoneal HSA administration completely rescued neurological damage and lethality, depending on dosage and administration frequency. Albumin infusion increased plasma bilirubin-binding capacity, mobilizing bilirubin from tissues to plasma. This resulted in reduced plasma Bf, forebrain and cerebellum bilirubin levels. We showed that, in our experimental model, Bf is the best marker to determine the risk of developing neurological damage. These results support the potential use of albumin administration in severe acute hyperbilirubinemia conditions to prevent or treat bilirubin neurotoxicity in situations in which exchange transfusion may be required.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a bilirubin $x krev $7 D001663
- 650 _2
- $a mozeček $x účinky léků $7 D002531
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a novorozenecká hyperbilirubinemie $x krev $x komplikace $7 D051556
- 650 _2
- $a novorozenecká žloutenka $x krev $x komplikace $7 D007567
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a nemoci nervového systému $x etiologie $x prevence a kontrola $7 D009422
- 650 _2
- $a fototerapie $x metody $7 D010789
- 650 _2
- $a sérový albumin $x aplikace a dávkování $7 D012709
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Bortolussi, Giulia $u International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 99 - 34149 - Trieste, Italy.
- 700 1_
- $a Schreuder, Andrea B $u Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Center for Liver, Digestive, and Metabolic Diseases, University of Groningen, Beatrix Children's Hospital-University Medical Center, Groningen, Hanzeplein 1,9713 GZ Groningen, The Netherlands.
- 700 1_
- $a Jašprová, Jana $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University in Prague, U Nemocnice 2, Prague, 120 00, Czech Republic.
- 700 1_
- $a Vitek, Libor $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University in Prague, U Nemocnice 2, Prague, 120 00, Czech Republic.
- 700 1_
- $a Verkade, Henkjan J $u Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Center for Liver, Digestive, and Metabolic Diseases, University of Groningen, Beatrix Children's Hospital-University Medical Center, Groningen, Hanzeplein 1,9713 GZ Groningen, The Netherlands.
- 700 1_
- $a Muro, Andrés F $u International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 99 - 34149 - Trieste, Italy.
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 5, č. - (2015), s. 16203
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26541892 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20161005 $b ABA008
- 991 __
- $a 20161005131804 $b ABA008
- 999 __
- $a ok $b bmc $g 1166308 $s 952624
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 5 $c - $d 16203 $e 20151106 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- LZP __
- $a Pubmed-20161005